Bearded Collie OA BEFORE Stem Cell Therapy By: MediVet Arizona … Continue reading →

2 months after stem cell therapy Eveybody agrees that the therapy works. There is very big improvment the way Toby walks now. By: Jacek Kozlowski … Continue reading →

By: Jet Villa, InterAksyon.com August 20, 2013 3:45 PM InterAksyon.com The online news portal of TV5 MANILA, Philippines Reminder for those who wish to have their stem cell therapy practice and products accredited: You have until August 31 to register, the Department of Health said Tuesday. Citing Administrative Order 2013-0012 issued March 18 this year, Health Secretary Enrique Ona said that while the Department of Health (DOH) supports scientific advancement in the field of cellular medicine, its priority is to protect the public from harm rather than give a blanket endorsement of its use or potential benefits. Those who need to seek accreditation include: health care facilities doing stem cell therapy (with the DOH) as well as companies that import, market, and produce stem cell products (with the Food and Drug Administration, which is under DOH). Ona said the DOH seeks to regulate stem cell therapy both as a recognized treatment modality and for research purposes. "This is to allay fears that unscrupulous individuals or groups will engage in unethical practices and subject naive patients to undue harm and unproven medical claims," he added. Among the DOH guidelines are: Ona conceded that there are only a limited number of medical … Continue reading →

By Philip C. Tubeza Philippine Daily Inquirer MANILA, PhilippinesSaying that doctors were exacting exorbitant fees for what is still experimental medicine, the Philippine College of Physicians (PCP) launched Tuesday an online petition urging the Department of Health (DOH) to put a stop to experimental stem cell therapies in the country. Human stem cell therapy for unproven indications is proliferating in the Philippines and posing serious safety issues to unknowing Filipinos The Philippine College of Physicians is alarmed by the false claims, misinformation and exorbitant fees for such stem cell treatments, read the petition on http://www.change.org. The PCP urged the DOH to issue a cease and desist order to all doctors performing such therapies as the Philippine Health Insurance Corp. (PhilHealth) clarified that stem cell therapy was not covered by the governments universal healthcare program. Cease and desist We, the undersigned, call on the (DOH) to issue a cease and desist order to all doctors, clinics and hospitals that [offer] human stem cell therapy for unproven indications until scientific evidence to support claims of efficacy and safety are approved by the Food and Drug Administration, it said. The PCP, the umbrella organization of Internal Medicine specialists in the country, said that … Continue reading →

CHEYENNE, WY- (ACCESSWIRE - August 20,2013) - Therapy Cells Inc (OTC Pink: TCEL) announces that on 13 February 2013, US patent US 11/702,895 was awarded to renowned scientist Dr Patrick Casey and Transplantation Ltd, for his transformational cell therapy, exclusively licensed to Therapy Cells Inc for use in human applications. This revolutionary science dispenses with the traditional notion that cells cannot divide once they are fully mature. Dr Casey has shown that adult cells, given the right environment, can in fact divide and be grown in the laboratory. These new cells can then be used for transportation back to damaged tissue in the body, to enact tissue and organ healing. The research team headed by Dr Casey has to date treated more than 80 horses including thoroughbreds, standardbreds, polo ponies and horses at the highest level of equestrian competition. "With a growing level of trial success in horses, Therapy Cells' target is to gain FDA approval, and in short order have human applications in human tendons," Dr Casey says. "An initial valuation of $30 million USD for our science and technology has been appraised. FDA approval for clinical use of this technology in humans, will likely increase this factor by … Continue reading →

CARLSBAD, CA--(Marketwired - Aug 21, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell-based therapies, announced today that it has entered into a master clinical research agreement with Duke University to conduct clinical trials research in Parkinson's disease using ISCO's innovative neural stem cell product. Mark Stacy, M.D., Vice Dean for Clinical Research, Neurology at Duke University School of Medicine and an internationally recognized leader in the field of Movement Disorders, including Parkinson's disease, will be the study's principal investigator. The research will be coordinated by the Duke Clinical Research Institute (DCRI), the world's largest academic clinical research organization, which is internationally recognized for conducting groundbreaking clinical trials. "We are pleased to have the opportunity to conduct the clinical trials related to ISCO's investigational stem cell therapy in Parkinson's disease patients," said Stacy. "Duke has an exceptional clinical trials team and we look forward to characterizing and understanding the safety and efficacy profile of this agent in the clinical trials setting." "We're tremendously excited to be working with such a world-class clinical research organization as Duke University," commented Dr. Ruslan Semechkin, Vice President of Research and Development at International Stem Cell Corporation. … Continue reading →